Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429791 | 0.97 | LMNA (0.53) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38654734 | 0.90 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL2230381 | 0.80 | — | — | |
| Sorbitol SCHEMBL29468856 | 0.75 | LMNA (0.69) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL28979520 | 0.75 | LMNA (0.69) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL23266184 | 0.74 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL10022040 | 0.74 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL20594083 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Adonitol SCHEMBL22572531 | 0.69 | LMNA (0.83) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL21837180 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146249-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP | VICO THERAPEUTICS B.V. (NL) | 2026-05-28 | — | — | US | disclosed |
| WO-2026099473-A1 | OLIGONUCLEOTIDES WITH NEW INTERNUCLEOSIDE LINKAGE | VICO THERAPEUTICS B.V. (NL) | 2026-05-15 | — | — | WO | disclosed |
| EP-4713459-A2 | ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF | LIFORDI IMMUNOTHERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4702144-A1 | ANTISENSE OLIGOMERS FOR TREATMENT OF CHRONIC KIDNEY DISEASE | Sarepta Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260048076-A1 | METHODS FOR DECREASING OR INHIBITING HUMAN L1 RETROTRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN | ALTOS LABS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4015631-B1 | NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-18 | — | — | EP | disclosed |
| US-20260014263-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4674964-A1 | RNA INTERFERENCE STRATEGIES TARGETING SMALL HEAT SHOCK PROTEIN B8 | Universiteit Antwerpen (BE) | 2026-01-07 | — | — | EP | disclosed |
| US-12502432-B2 | Bicyclic peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250382325-A1 | DEPROTECTION PROCESSES AND CATION SCAVENGERS FOR USE IN THE SAME | EXACTMER LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| WO-2022120410-A1 | COMPOSITIONS AND METHODS FOR TREATING TARDBP ASSOCIATED DISEASES | Perron Institute for Neurological and Translational Science Limited (AU) | 2022-06-16 | — | — | WO | disclosed |
| US-11345915-B2 | RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders | VICO THERAPEUTICS B.V. (NL) | 2022-05-31 | — | — | US | disclosed |
| CN-109415399-B | Novel method for producing oligonucleotides | 葛兰素史克知识产权开发有限公司 | 2022-05-24 | — | — | CN | disclosed |
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3998339-A1 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-107921092-B | Peptide oligonucleotide conjugates | 萨勒普塔医疗公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3728585-B1 | NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-20220072143-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-03-10 | — | — | US | disclosed |
| EP-3963077-A1 | TREATMENT FOR SOD1 ASSOCIATED DISEASE | Black Swan Pharmaceuticals, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3955966-A1 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Sarepta Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11338041-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SMN1; SMN2, UTRN, RBM17 | LMNA 904/4885L3MBTL1 283/4885TDP1 827/4885 |
| US-12502432-B2 | Bicyclic peptide oligonucleotide conjugates | MUSK, MTPN, TNNC1 | LMNA 1927/4885L3MBTL1 116/4885TDP1 854/4885 |
| US-20220072143-A1 | Peptide Oligonucleotide Conjugates | MYOF, MUSK, MTPN | LMNA 3089/4885L3MBTL1 133/4885TDP1 879/4885 |
| US-20260146249-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP | APP, PSEN2, PSEN1 | LMNA 69/4885L3MBTL1 270/4885TDP1 216/4885 |
| US-20260014263-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SSU72, TNNC1, MUSK | LMNA 906/4885L3MBTL1 34/4885TDP1 481/4885 |
| US-20260048076-A1 | METHODS FOR DECREASING OR INHIBITING HUMAN L1 RETROTRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN | POT1, FBL, HNRNPA1 | LMNA 23/4885L3MBTL1 29/4885TDP1 22/4885 |
| US-20250382325-A1 | DEPROTECTION PROCESSES AND CATION SCAVENGERS FOR USE IN THE SAME | ACMSD, DCTD, MSR1 | LMNA 56/4885L3MBTL1 2633/4885TDP1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.